Introduction {#s0005}
============

In many industrialized nations, prostate adenocarcinoma is one of the most common malignant diseases in men [@bb0005]. Prostate cancer (PC) is considered clinically heterogeneous. Some prostate cancers are indolent and localized, while others are aggressive and easily spread to other parts of the body. Therefore, it is necessary to understand key features related to tumor progression and invasiveness. Many cases of prostate cancer are multifocal; most radical prostatectomy specimens harbor morphologically and clonally distinct tumor foci [@bb0010], [@bb0015], [@bb0020]. Studies of metastatic tumors from primary PC have suggested that all of those tumors evolved from one clone, as they share a significant portion of genetic alterations [@bb0025], [@bb0030]. The characteristics and diversity of a clone may explain the aggressiveness of prostate cancer.

Therefore, it is important to perform a comprehensive genomic and transcriptomic characterization of the primary cancer lesion to understand the biology of the tumor and the factors associated with tumor progression. However, major factors that lead to tumor heterogeneity during prostate cancer progression are still not clear. Recently, next-generation sequencing provided a molecular portrait of genomic alterations. Furthermore, intratumor heterogeneity (ITH) has been inferred by clonality analysis [@bb0035]. In various types of cancer, the characterization of clonal heterogeneity may provide useful information for predicting patient prognosis and treatment response.

Herein, we investigated factors that are associated with ITH of prostate cancer through comprehensive genomic and transcriptomic analysis. We also investigated genomic alterations, altered pathways, and clinical features as the indicators of high ITH.

Materials and Methods {#s0010}
=====================

Dataset Collection {#s0015}
------------------

Genomic and transcriptomic alterations including somatic mutations, copy number alterations, and gene fusions were collected from The Cancer Genome Atlas Research Network (The Cancer Genome Atlas Research Network 2015) [@bb0040]. Gene expression data from RNA-seq were obtained from GDAC Firehose (<http://gdac.broadinstitute.org>). A total of 85 samples with clonality information were used to determine the association between genomic alteration and expression profile.

Gene Expression Analysis {#s0020}
------------------------

Differentially expressed genes (DEGs) were identified using DESeq R package ([www.huber.embl.de/users/anders/DESeq/](http://www.huber.embl.de/users/anders/DESeq){#ir0010}). Significant DEGs by both ≥2-fold change and adjusted *P* value \<.05 were chosen. In order to identify overrepresented functions of an interesting group, gene set enrichment test was performed using Gene Set Enrichment Analysis (software.[broadinstitute.org/gsea](http://broadinstitute.org/gsea){#ir0015}/), based on REACTOME pathway database in the Molecular Signatures Database (MSigDB). To estimate the fractions of immune-associated cell types including CD8-positive T cells, CIBERSORT was applied using RNA-seq expression profiles [@bb0045]. It can infer relative proportions of each immune cell types using gene expression profiles.

Clonality and Tumor Purity Information {#s0025}
--------------------------------------

Clonality information was obtained from a pan-cancer analysis of the ITH, measured using PyClone and EXPANDS tools [@bb0035]. The number of subclones ranged from one to eight and represented the ITH level. In order to categorize high and low ITH, we defined a tumor as an oligoclone when there were one or two subclones; otherwise, the tumor was defined as a multiclone [@bb0050]. Tumor purity information was collected from pan-cancer analysis of the tumor purity [@bb0055]. In brief, the purity levels were arbitrarily chosen from multiple estimators. The consensus purity estimation method is the median value for estimators after normalization.

Statistical Analysis {#s0030}
--------------------

The significance of clinical outcomes of the selected genes was plotted using Kaplan-Meier survival analysis using the survival package in R (<http://CRAN.R-project.org/package=survival>). Log-rank test was used for survival analysis. Fisher\'s exact test was used for the statistical analysis of ITH and genomic mutations. *P* \< .05 was considered statistically significant. Information gain (IG) was used to select the informative features for discriminating cancers with high clonality. IG for tumor samples *D* and a feature *a* is defined as [@bb0060]:$$\mathit{IG}\left( {D,a} \right) = \mathit{Entropy}\left( D \right) - \sum\limits_{v \in \mathit{value}{(a)}}\frac{D_{v}}{D}\mathit{Entropy}\left( D_{v} \right)$$

where value(*a*) is the set of all possible values for feature *a* and *D*~*v*~ is the subset of *D* which the feature *a* has value *v*.

Results {#s0035}
=======

Genomic Profiles According to Degree of ITH {#s0040}
-------------------------------------------

A total of 85 patients having clonality information with prostate cancer were evaluated. Patient characteristics according to clonality are shown in [Table 1](#t0005){ref-type="table"}. Here, an oligoclone had one or two subclones, and a multiclone had more than two subclones. Prostate-specific antigen (PSA) is one of the major markers used to diagnose prostate cancer. In the prostate cancer cohort, PSA level (*n* = 472) was significantly correlated with clinical outcome ([Supplementary Figure S1](#f0025){ref-type="graphic"}). Although the association between tumor heterogeneity and level of PSA is not prominent, high level of PSA (\>1.5) was more frequently observed in the group with multiclone, indicating high ITH ([Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"}*A*). In the oligoclone group, only two patients had a high level of PSA, while there were seven such patients in the multiclone group. Furthermore, the average level of PSA was 0.28 in the oligoclone group and 1.67 in the multiclone group ([Table 1](#t0005){ref-type="table"}). The analysis suggested that the level of tumor progression or invasiveness is substantially associated with ITH and PSA levels.

Several factors such as average PSA level, tumor mutation burden (TMB), and CD8 scores are associated with the number of clones ([Figure 2](#f0010){ref-type="fig"}). The data demonstrated that the level of PSA increased as the number of clones increased. TMB also increased slightly when the number of clones increased. On the other hand, the activation score of CD8 generally declined with the accumulation of clones. These results were not likely affected by tumor purity estimated by four different kinds of measurements including immunohistochemistry, as tumor purities of samples in PC were not different according to number of subclones (Supplementary Table [S1](#ec0005){ref-type="supplementary-material"}).

Moreover, we measured the activation degree of immune cells adjacent to cancer cells using decomposition of RNA-sequencing data. When comparing the immune profiling based on tumor heterogeneity, the activation score of T cell (CD8+) showed slight differences (*P* = .05) between tumors with oligoclones and those with multiclones [(Supplementary Figure S2](#f0030){ref-type="graphic"}). On average, patients who had high heterogeneity showed a lower immune activation score of T cell compared to those with low heterogeneity. Generally, cancer cells are known to develop immunosuppression or avoidance [@bb0065]. Our analysis indicated that the immune avoidance mechanism works better by reducing the activation of T cells in multiclonal than oligoclonal prostate cancer.

Association of *PTEN* Deletion and ITH {#s0045}
--------------------------------------

We also analyzed the association between ITH and mutational profiles, including somatic mutations and copy number alterations (CNAs), from whole-exome sequencing data. While most alterations did not showed any difference in degree of heterogeneity, there were substantial deviations in *PTEN* CNA ([Figure 3](#f0015){ref-type="fig"}*A*). To observe the genomic factors that can lead to a separation of clonality, information gain (IG) was adopted, and *PTEN* CNA among many factors showed the highest IG score. Other subsets such as *PTEN* mutation, *ETV4* fusion, and *SPOPL* CNA also ranked high with regard to IG score but were not considered as important as *PTEN* CNA.Figure 1Heatmap of genomic alterations according to clonality. Landscape of somatic mutations with high frequency and copy number alterations from 85 prostate tumor samples (8 in 1 clone, 27 in 2 clones, 27 in 3 clones, and 23 in over 4 clones). When a tumor sample had one or two subclones, it was defined as an oligoclone; otherwise, the tumor was defined as a multiclone. Bar plot at the top represents PSA values (log10). Patient samples with a level greater than zero are highlighted in red.Figure 1Figure 2Correlations between ITH and several factors in prostate cancer samples. (A) Bar plot of average PSA values according to number of clones. (B) Box plot of TMB according to number of clones. (C) Box plot of contribution scores of CD8 T-cell signature according to number of clones.Figure 2Table 1Demographic and Clinical Characteristics of Prostate Cancer PatientsTable 1CharacteristicOligoclone (*n* = 35)Multiclone (*n* = 50)*P* ValueAge, median (years)62 (44-71)61.5 (47-73).904PSA value, average0.28 (0-4.09)1.67 (0-37.4).108Preoperative PSA, average11.15 (2.2-87)10.54 (1.6-37.4).831Gleason Score.407 3 + 35 (14.3%)5 (10.0%) 3 + 410 (28.6%)19 (38.0%) 4 + 311 (31.4%)9 (18.0%) ≥ 89 (25.7%)17 (34.0%)Tumor cellularity (pathology).374 \<20%2 (5.7%)1 (2.0%) 21%-40%3 (8.6%)6 (12.0%) 41%-60%7 (20.0%)8 (16.0%) 61%-80%12 (34.3%)26 (52.0%) 81%-100%11 (31.4%)9 (18.0%)Pathologic stage.454 pT2a/b1 (2.9%)2 (4.0%) pT2c14 (40.0%)19 (38.0%) pT3a8 (22.9%)19 (38.0%) pT3b8 (22.9%)9 (18.0%) pT43 (8.6%)1 (2.0%) Not available1 (2.9%)0 (0.0%)Ethnicity.895 Caucasian32 (91.4%)45 (90.0%) African descent2 (5.7%)4 (8.0%) Asian1 (2.9%)1 (2.0%)Figure 3*PTEN* deletion as an indicator of tumor heterogeneity in prostate cancer. (A) Contribution score of genomic and transcriptomic features. Information gain for each feature was measured between oligo- and multiclonal samples. (B) Comparison of clonality between tumor samples with *PTEN* deletion and those with wild type. (C) Comparison of clonality among diploid, homozygous, and heterozygous *PTEN* deletion.Figure 3

Tumors with wild type and those with *PTEN* deletion showed considerable differences between high- and low-heterogeneity groups (*P* = .0027; Fisher\'s exact test) ([Figure 3](#f0015){ref-type="fig"}*B*). Interestingly, PCs with *PTEN* deletion possessed an overwhelmingly large proportion of multiclone tumors. Based on this result, we think that the *PTEN* deletion is one of the key markers associated with ITH.

We also analyzed the clonality among diploid, homozygous, and heterozygous *PTEN* deletion ([Figure 3](#f0015){ref-type="fig"}*C*). Our analysis revealed that multiclone PCs are notably enriched in heterozygous *PTEN* deletion compared to diploid or homozygous deletion (*P* = .001). In some types of PCs, *PTEN* heterozygous and homozygous deletions have different characteristics such as Gleason score [@bb0070], and our study suggested different ITH patterns in the two studied groups. However, further clinical and biological investigation is warranted.

Functional Enrichment of Tumors with *PTEN* Deletion and ITH {#s0050}
------------------------------------------------------------

*PTEN* CNA was positively correlated with mRNA expression ([Figure 4](#f0020){ref-type="fig"}*A*). As expected, the gene expression of genes with homozygous and heterozygous *PTEN* deletion was lower than that with diploid and gain. Moreover, we studied the kinds of genes differentially affecting clonality according to *PTEN* deletion. In order to identify genes associated with both *PTEN* deletion and clonality, we extracted DEGs for six possible combinations for *PTEN* deletion (+ and −) and clonality (oligo and multi). Among them, only two combinations had significantly differentially expressed genes ([Figure 4](#f0020){ref-type="fig"}*B*). One was the test for PTEN Del (+) & multiclone vs. PTEN Del (−) & oligoclone. The other was the test for PTEN Del (+) & multiclone vs. PTEN Del (−) & multiclone. Several differently expressed genes such as *PTEN*, *CDC42EP5*, *RNLS, GP2*, *NETO2*, *and AMPD3* were correlated with tumor heterogeneity in the presence of *PTEN* deletion (≥2-fold change, adjusted *P* value \<.05). In other words, high heterogeneity of a tumor with *PTEN* deletion may be dominantly driven by the expression of those genes.Figure 4Gene expression and function associated with *PTEN* deletion and tumor heterogeneity. (A) Correlation between *PTEN* deletion and corresponding gene expression. Expression values are the log-transformed normalized read counts. (B) The result of DEG analysis for six possible combinations for *PTEN* deletion (+ and −) and clonality (oligo and multi). DEGs were found in only two tests: 1) PTEN Del (+) & multiclone vs. PTEN Del (−) & oligoclone, 2) PTEN Del (+) & multiclone vs. PTEN Del (−) & multiclone. (C) Enriched pathways associated with *PTEN* deletion and tumor heterogeneity. This result was obtained from gene set enrichment analysis for PTEN Del (+) & multiclone vs. PTEN Del (−) & oligoclone. (D) Enrichment of genes involved in the PI3K cascade pathway.Figure 4

According to previous studies, several pathways such as WNT, PI3CA, and androgen receptor signaling are known to regulate the progression of prostate cancer [@bb0075]. Particularly, the PI3CA pathway was significantly affected by tumor heterogeneity ([Figure 4](#f0020){ref-type="fig"}, *C* and *D*). It is assumed that the altered PI3CA pathway is closely related to higher ITH with *PTEN* deletion.

Discussion {#s0055}
==========

In this study, we presented genomic and transcriptomic factors associated with the degree of ITH. Deletion of *PTEN* tumor suppressor gene occurs at high frequency in prostate cancer and is associated with clinical outcome and aggressive metastatic potential [@bb0080], [@bb0085]. Although many studies regarding *PTEN* deletion in prostate cancer have been reported, the association with ITH has not been clarified. We demonstrated that it was frequently observed in tumors with high heterogeneity. It is still questionable whether the alteration of *PTEN* directly or indirectly causes tumor heterogeneity during prostate cancer progression.

Previous studies have reported that most *PTEN* deletions of primary tumors were concordantly found in metastatic sites [@bb0025], [@bb0030], [@bb0090]. It is highly possible that *PTEN* deletions are early occurring mutations as they tend to be observed in multiple lesions. A study on ERG rearrangements and *PTEN* deletions in prostate cancer indicated that they are early events during tumor progression [@bb0070]. That prior study has reported that *PTEN* heterozygous deletions showed higher frequency than homozygous deletions in diverse tissues obtained from benign prostate tissue to high-grade prostatic intraepithelial neoplasia and prostate cancer. In our study, both types showed similar frequency and increased ITH. However, ITH was higher in heterozygous deletions than in homozygous.

A number of studies have suggested that tumor infiltrating immune cells can accelerate tumor invasion and metastasis [@bb0095], [@bb0100], [@bb0105], [@bb0110]. However, the most recent study has demonstrated that progressing metastases showed the characterization of immune cell exclusion, while repressing and stable metastases exhibited infiltration of CD8+ T cells in ovarian cancers [@bb0115]. In our study, the activation score of CD8-positive T cell or cytotoxic T cell was negatively correlated with ITH, indicating that the pattern observed from our analysis is consistent with the characteristics of cancer progression. The heterogeneity of clones can vary depending on the immune-microenvironment of the surrounding tumor in prostate cancer.

We demonstrated that the expression of several genes was significantly associated with ITH potentially via *PTEN* deletion. These genes were *PTEN*, *CDC42EP5*, *RNLS, GP2*, *NETO2*, and *AMPD3*. Overexpression of Neuropilin and tolloid-like 2 (*NETO2*) has been found in many cancer types including proliferating hemangiomas and colorectal carcinoma [@bb0120], [@bb0125], [@bb0130] and thus could be considered as a potential biomarker in tumor progression. Recent study have suggested that adenosine monophosphate deaminase 3 (*AMPD3*) deletion suppresses the proliferation, migration, and invasion of gastrointestinal stromal tumor [@bb0135]. *AMPD3* expression is positively correlated with *ERG* overexpression and *PTEN* inactivation in prostate cancer [@bb0140], [@bb0145]. This result suggests that this abnormal alteration is tightly correlated with tumor heterogeneity and may be useful in the development of prognostic markers or novel drug targets in prostate cancer.

In conclusion, progression of ITH could foster tumor evolution in association with *PTEN* deletion, which is one of the key mechanisms in prostate cancer progression. Genes identified from ITH analysis could potentially serve as a biomarker promoting ITH or a therapeutic target.

The following are the supplementary data related to this article.Supplementary Figure 1Overall survival according to PSA score.Supplementary Figure 1Supplementary Figure 2Activation score of T cells (CD8) between tumors with oligoclones and those with multiclones.Supplementary Figure 2Supplementary Table 1Tumor Purity of Prostate Cancer Samples. Average and Standard Deviation Are Shown According to Number of Subclones.Supplementary Table 1

Conflicts of Interest {#s0060}
=====================

Conflict of interest relevant to this article was not reported.

The study was supported in part by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03034779).

Grant support: The study was supported in part by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B03034779).

Disclosure of potential conflicts of interest: There are no potential conflicts of interest to disclose.

[^1]: These authors contributed equally to this work.
